NYSE: ITGR · Medical Devices
Integer Holdings (ITGR) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Integer Holdings (ITGR) at $153.83 a share. The stock last closed at $126.97, which puts the model's fair value 21.2% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 16 Nov 2026. Integer Holdings Corporation.
The report adds the live price, the price chart, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $157.64 to $153.83 (-2.4%). The multiple the model anchors on moved, lowering the fair value: most of the move.
What the model makes of itThe price of $126.97 is 21.2% below it: Undervalued, on a medium evidence grade.
What's nextNext report on 18 Feb 2027. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give ITGR?
The calibrated range for ITGR over 63 trading days is $123.02 to $182.75. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $116.00 to $200.28. In 71% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, with operations in the United States, Puerto Rico, Costa Rica and other international regions.
Faircurve's model put the fair value of Integer Holdings at $153.83 a share on 14 Nov 2026. The previous run, on 7 Nov 2026, gave $157.64, so the fair value moved -2.4%. In the model's own words, the multiple it anchors on moved, lowering the fair value: most of the move. The calibrated range over 63 trading days is $123.02 to $182.75, built from the fair value because there is no live options data for the stock. Ranges built this way held the price 60% of the time at this horizon, across 13,250 past valuations. The evidence grade is Medium. It looks at how complete the inputs are, how the comparable companies agree, and how wide the outcomes are. It does not say whether the fair value is right.
The model gives Integer Holdings an overall quality score of 48 out of 100 against comparable companies. Stability scores 99, with five-year EBITDA margin downside volatility at 0.8 pts against a peer median of 5.5 pts. Growth quality scores 24, with trailing revenue growth of 7.6% against a peer median of 17.5%. The model compares the company with eight others: LivaNova, Haemonetics, TransMedics, Neogen, UFP Technologies, Bruker, Globus Medical and Bio-Rad.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does ITGR report earnings, and how has the stock reacted?
Integer Holdings's next earnings report is scheduled for 18 Feb 2027. Companies can move their dates.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across ITGR's last 8 reports, ignoring direction, was 1.2%.
How does ITGR score on business quality?
Integer Holdings's overall quality score is 48 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 49 | 4.7%ROIC | -2.9% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 52 | 0.79xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 24 | 7.6%Revenue growth, trailing | 17.5% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 63 | 2.3%Net buybacks / market value | 0.2% |
| Balance sheetNet debt to EBITDA and interest coverage. | 19 | 4.65xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 99 | 0.8 ptsEBITDA margin downside volatility, 5y | 5.5 pts |
How does ITGR compare with similar companies?
The companies in medical devices closest to Integer Holdings in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| LIVN LivaNova PLC | $92.44 | $101.82 | +10.1% | Fairly valued |
| HAE Haemonetics Corporation | $121.34 | $120.83 | -0.4% | Fairly valued |
| TMDX TransMedics Group, Inc. | $92.21 | $102.39 | +11.0% | Fairly valued |
| NEOG Neogen Corporation | $10.88 | $10.11 | -7.1% | Fairly valued |
| UFPT UFP Technologies, Inc. | $298.54 | $266.65 | -10.7% | Fairly valued |
| BRKR Bruker Corporation | $60.62 | $64.27 | +6.0% | Fairly valued |
| GMED Globus Medical, Inc. | $70.50 | $76.21 | +8.1% | Fairly valued |
| BIO Bio-Rad Laboratories, Inc. | $360.26 | $340.60 | -5.5% | Fairly valued |
What the comparable companies' multiples alone would give for ITGR, the peer-implied price, is $570.87 a share on this run. The fair value weighs that against the company's own multiple.
Integer Holdings at a glance
Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions.
- Market value
- $4.3B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $1.9B
- Consensus revenue growth, next fiscal year
- -1.8%
- Analysts with estimates
- 2
- Beta to the US market
- 0.57
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. ITGR was among them.
How the fair value is worked out: the model prices Integer Holdings on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for ITGR was $157.64. As of 14 Nov 2026 it is $153.83, a change of -2.4%. The multiple the model anchors on moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Integer Holdings's valuation
Is Integer Holdings stock undervalued or overvalued?
On Faircurve's model, ITGR reads as Undervalued as of 14 Nov 2026. The model's fair value is $153.83 a share against a last close of $126.97, a gap of +21.2%.
What is ITGR's fair value?
$153.83 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $116.00 to $200.28.
What price range does the model give ITGR?
$123.02 to $182.75 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.
When does Integer Holdings report earnings next?
The next report is scheduled for 18 Feb 2027. Companies can move their dates.
How much has ITGR moved on past earnings reports?
Across its last 8 reports the median two session move was 1.2%, ignoring direction. The largest was -33.2% around the report of 23 Oct 2025.
How confident is the model in this valuation?
The model's evidence grade for ITGR is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on ITGR
The model holds no idea open on ITGR today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on ITGR with their outcomes. A free account is enough.